Kindred Bio stock soars 43% on deal to be bought by Elanco for $440M

Jun. 16, 2021 6:41 AM ETElanco Animal Health Incorporated (ELAN)ELANBy: Mamta Mayani, SA News Editor9 Comments
  • Elanco Animal Health (NYSE:ELAN) inks agreement to acquire Kindred Biosciences (NASDAQ:KIN), up 43% premarket which will further accelerates Elanco's expansion in pet health market.
  • Under the terms of the deal, Elanco will acquire all outstanding stock of Kindred at $9.25/share, or ~$440M.
  • Kindred Bio brings three potential dermatology blockbusters expected to launch through 2025, as well as a number of additional R&D programs for other chronic disorders, including canine parvovirus.
  • Elanco anticipates the combination will add ~$100M to its innovation revenue expectation of $500M to $600M by 2025, with significant opportunity beyond the period.
  • The transaction is expected to close in Q3 2021.
  • Elanco also reaffirmed Q2 and FY21 revenue guidance of $1,225M to $1,255M (consensus $1.24B), and $4,670M to $4,710M (consensus $4.7B), respectively.
  • ELAN will host a conference call today at 8:00 am ET to discuss the announcement.

Recommended For You

Comments (9)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.